Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$30.28
-0.6%
$30.18
$22.97
$36.45
$4.99B0.441.73 million shs1.45 million shs
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$129.30
0.0%
$116.53
$73.04
$129.49
$8.35B0.892.05 million shs3.48 million shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$29.51
-4.9%
$36.67
$29.04
$60.37
$2.79B0.26918,288 shs5.49 million shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$21.01
-3.2%
$22.33
$16.60
$28.47
$1.54B1.581.14 million shs891,769 shs
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$32.73
-4.0%
$34.06
$16.01
$44.34
$3.64B0.99914,976 shs1.02 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+1.60%+5.95%-1.93%+12.81%+32.38%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
+0.61%+0.83%+1.06%+59.98%+11.54%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-25.12%-20.82%-17.28%-9.11%-26.92%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
+0.14%+3.58%-16.92%-11.35%+5.49%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-4.43%-6.45%-14.80%+15.37%+99.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alkermes plc stock logo
ALKS
Alkermes
4.9128 of 5 stars
4.43.00.04.22.92.51.9
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.6356 of 5 stars
2.14.00.00.02.30.80.6
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
4.028 of 5 stars
3.51.00.03.82.42.50.6
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.697 of 5 stars
3.42.00.00.02.42.50.6
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
3.2747 of 5 stars
3.45.00.00.02.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.83
Moderate Buy$40.0031.96% Upside
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
2.24
Hold$128.25-0.84% Downside
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2.93
Moderate Buy$85.36189.90% Upside
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.75
Moderate Buy$33.2559.53% Upside
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2.80
Moderate Buy$54.2867.32% Upside

Current Analyst Ratings Breakdown

Latest BPMC, ALKS, RARE, ZLAB, and SDGR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$88.00 ➝ $65.00
7/3/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$28.00
6/30/2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$73.00 ➝ $75.00
6/20/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$64.00
6/17/2025
Alkermes plc stock logo
ALKS
Alkermes
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$33.00 ➝ $42.00
6/17/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.00
6/4/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold$83.00 ➝ $129.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$132.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.51B3.30$2.68 per share11.31$9.05 per share3.35
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$508.82M16.42N/AN/A$4.70 per share27.52
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$560.23M4.97N/AN/A$2.76 per share10.67
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$207.54M7.37N/AN/A$5.78 per share3.61
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$398.99M9.03N/AN/A$7.68 per share4.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$367.07M$2.0914.5122.131.8623.30%27.52%17.98%7/23/2025 (Estimated)
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A198.98N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/5/2025 (Estimated)

Latest BPMC, ALKS, RARE, ZLAB, and SDGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.54N/AN/AN/A$171.34 millionN/A
8/7/2025Q2 2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.27N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.42N/AN/AN/A$125.66 millionN/A
7/30/2025Q2 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.83N/AN/AN/A$52.03 millionN/A
7/23/2025Q2 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.42N/AN/AN/A$343.20 millionN/A
5/8/2025Q1 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million
5/7/2025Q1 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million
5/6/2025Q1 2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million
5/1/2025Q1 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.32$0.13-$0.19$0.13$307.53 million$306.51 million
5/1/2025Q1 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/AN/AN/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
N/A
3.33
2.92
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.01
2.80
2.75
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/A
2.40
2.24
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
3.45
3.45
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/A
3.26
3.09

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
97.67%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79.05%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
41.65%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.40%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
4.21%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5.50%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
8.60%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
4.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
1,800164.90 million157.65 millionOptionable
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
64064.58 million61.86 millionOptionable
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1,29494.54 million89.34 millionOptionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79073.38 million67.07 millionOptionable
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
1,869111.08 million105.57 millionOptionable

Recent News About These Companies

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - What's Next?
Zai Lab FY2025 EPS Estimate Decreased by Cantor Fitzgerald
FY2026 EPS Estimates for Zai Lab Raised by Leerink Partnrs
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alkermes stock logo

Alkermes NASDAQ:ALKS

$30.28 -0.18 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$30.64 +0.36 (+1.19%)
As of 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$129.30 -0.03 (-0.02%)
Closing price 04:00 PM Eastern
Extended Trading
$129.30 0.00 (0.00%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Ultragenyx Pharmaceutical stock logo

Ultragenyx Pharmaceutical NASDAQ:RARE

$29.51 -1.53 (-4.93%)
Closing price 04:00 PM Eastern
Extended Trading
$29.62 +0.11 (+0.39%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$21.01 -0.70 (-3.22%)
Closing price 04:00 PM Eastern
Extended Trading
$21.30 +0.29 (+1.38%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Zai Lab stock logo

Zai Lab NASDAQ:ZLAB

$32.73 -1.35 (-3.96%)
Closing price 04:00 PM Eastern
Extended Trading
$32.73 +0.00 (+0.01%)
As of 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.